危重症患者炎症状态下抗生素剂量个体化:叙述性综述
危重症患者病理生理改变可致标准抗生素剂量下药物暴露不足或过量,炎症对药代/药效学影响尚不明确。本文综述炎症与抗生素PK/PD的关联,以及生物标志物、治疗药物监测和模型引导精准给药在优化剂量中的作用,提出未来应结合炎症标志物与大数据预测药物暴露。
要点
- 危重症患者标准剂量抗生素可能暴露不足或过量,影响疗效与安全性。
- 治疗药物监测和群体PK模型可改善PK/PD靶值达标。
- 炎症生物标志物指导抗生素剂量的潜力尚不明确。
核心结论
- 炎症与危重症患者抗生素PK/PD的关联尚不明确,需将炎症标志物纳入PK/PD模型并利用大数据预测药物暴露。
研究设计与样本
- 叙述性综述,描述危重症患者炎症与抗生素PK/PD的关联及生物标志物、治疗药物监测和模型引导精准给药的作用。
主要发现
- 危重症患者广泛病理生理改变可致标准剂量抗生素暴露不足或过量,分别增加治疗失败或毒性风险。
- 治疗药物监测通过测血药浓度并调整剂量可改善PK/PD靶值达标。
- 群体PK模型可用于预测药物暴露并个体化调整剂量(模型引导精准给药)。
- 炎症生物标志物指导抗生素剂量的潜力尚不明确。
临床怎么用
- 可考虑用治疗药物监测和模型引导精准给药优化危重症患者抗生素剂量。
- 炎症生物标志物指导剂量调整的证据不足,暂不宜常规用于剂量决策。
局限性
- 为叙述性综述,未提供系统检索或定量合并数据。
- 炎症对抗生素PK/PD的影响及生物标志物指导剂量的潜力尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Due to extensive pathophysiological changes in critically ill patients, standard dosing of antibiotics may lead to inadequate drug exposure. This is concerning, as insufficient plasma drug concentrations may lead to treatment failure, whereas excessive drug exposure may increase the risk of toxic adverse events. The role of inflammation as a factor influencing the pharmacokinetics (PK) and pharmacodynamics (PD) of antibiotics remains largely unknown. PK/PD target attainment of antibiotics can be improved through therapeutic drug monitoring, i.e., measurement of drug concentrations in the blood with subsequent dosage adjustment to reach a certain target. Besides, population PK models may be used to predict drug exposure and tailor dosing in an individual patient (model-informed precision dosing). Inflammatory biomarkers have been proposed to measure inflammation levels and guide antibiotic treatment. However, their potential to guide antibiotic dosing is unclear. This narrative review describes associations between inflammation and PK/PD of antibiotics in critically ill patients, and the role of biomarkers, therapeutic drug monitoring and model-informed precision dosing in improving antibiotic dosing. A focus of future research should be on the interplay between inflammation and PK/PD of antibiotics by including inflammatory biomarkers in PK/PD models and using big data to predict antibiotic exposure in critically ill patients.
引用
- Dräger S, Minichmayr IK, Alipanah-Lechner N, et al. Dose individualisation of antibiotics in critically ill patients with inflammation: A narrative review. Br J Clin Pharmacol. 2025. PMID: 40813897. doi:10.1002/bcp.70185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。